Clinical Roundup Baylor study points to strategy to suppress prostate cancer growth October 21, 2022Vol.48 No.38
Drugs & Targets Pluvicto receives positive CHMP opinion for prostate cancer October 21, 2022Vol.48 No.38
Clinical Roundup Genomic testing can identify African American prostate cancer patients with high-risk disease September 23, 2022Vol.48 No.34
Drugs & Targets FDA approves darolutamide for metastatic hormone-sensitive prostate cancer September 09, 2022Vol.48 No.32
In Brief Fox Chase researchers win $1.4M DoD Prostate Cancer Health Equity Grant July 08, 2022Vol.48 No.27
Clinical Roundup Roswell Park study: Targeting HSP60-ClpP axis may improve outcomes in prostate cancer June 03, 2022Vol.48 No.22
Clinical Roundup Genetic testing changes cancer treatment plans, Invitae studies suggest June 03, 2022Vol.48 No.22
Clinical Roundup Cedars-Sinai Cancer study shows hormone therapy + pelvic lymph node treatment improves survival in prostate cancer May 27, 2022Vol.48 No.21
Drugs & Targets Paige Prostate Biomarker Suite receives CE-IVD and UKCA marks May 20, 2022Vol.48 No.20
